A Universidade de Évora (UÉ) vai disponibilizar, no próximo ano letivo, um mestrado em Ciências Biomédicas e da Saúde, alinhado com o novo Hospital Central do Alentejo, que está em ...

We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other best drug stocks to buy now.

O ator Ralph Macchio defendeu a existência do novo filme da franquia ‘Karatê Kid’. Com lançamento previsto para o próximo mês de maio, ‘Karatê Kid: Lendas’, vai unir o personagem Daniel LaRusso ...

Capitão América: Admirável Mundo Novo é o próximo filme do famoso herói da Marvel. Desta vez, o filme dá continuidade à minissérie de televisão Falcão e o Soldado Invernal, onde o ...

Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this. On rare occasions, our expert team of analysts issues a “Double Down” stock ...

Novo Nordisk A/S today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn and a 26% rise in operating profit to ~$17.91bn for 2024. The company’s GLP-1 drugs, Ozempic ...

Novo Nordisk A/S dominates in diabetes and weight-loss drugs, particularly with semaglutide, making it a strong buy. Record investments in 2024 to enhance supply chain and production capacity ...

Novo Nordisk's U.S.-listed shares rose 5% in intraday trading after the Ozempic and Wegovy maker's better-than-estimated quarterly results offset slower 2025 sales growth projections amid ...

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid soaring demand for its Wegovy obesity drugs. Net profit for the fourth ...

Europe's largest pharmaceutical firm, Novo Nordisk, reported fourth-quarter earnings that surpassed analysts' expectations. The company’s shares jumped more than 6% at the market open in Europe ...

Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t its wildly popular weight-loss drugs. Novo Nordisk said its fourth ...

Danish drugmaker Novo Nordisk (NVO) reported fourth quarter and full year 2024 earnings Wednesday, beating Wall Street's expectations and bumping its stock up more than 4% at market open.